Department of Radiology, University of Alabama at Birmingham, 619 19th St S, JT N325, Birmingham, AL, 35249, USA.
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Curr Urol Rep. 2021 Jan 6;22(1):3. doi: 10.1007/s11934-020-01020-y.
The goal of this paper was to review the novel treatment modality of high-intensity transurethral directional ultrasound for prostate cancer.
Prostate cancer is a heterogeneous disease with some patients electing for active surveillance and focal therapies instead of definitive treatment with radical prostatectomy or radiation therapy. Prostate MRI has become a cornerstone of prostate cancer diagnosis, targeted biopsy, and treatment planning. Transurethral high-intensity directional ultrasound allows for MRI-guided ablation of the prostate gland with the ability to contour boundaries and spare critical structures, such as the neurovascular bundle and urinary sphincter. Although results are still emerging, this may offer patients a new option for focal therapy with a favorable side-effect profile. High-intensity transurethral directional ultrasound is an emerging treatment modality for both whole-gland and focal ablation with promising early results. Further research is needed to establish safety, tolerability, and long-term oncologic outcomes.
目的综述：本文旨在综述高强度经尿道定向超声治疗前列腺癌这一新型治疗方法。
最新发现：前列腺癌是一种异质性疾病，一些患者选择主动监测和局灶治疗，而不是采用根治性前列腺切除术或放射治疗。前列腺 MRI 已成为前列腺癌诊断、靶向活检和治疗计划的基石。经尿道高强度定向超声可实现 MRI 引导下的前列腺消融，具有描绘边界和保护关键结构（如神经血管束和尿括约肌）的能力。尽管结果仍在不断涌现，但这可能为患者提供一种新的局灶治疗选择，具有良好的副作用特征。高强度经尿道定向超声是一种新兴的全腺和局灶消融治疗方法，早期结果令人鼓舞。需要进一步的研究来确定其安全性、耐受性和长期肿瘤学结果。
